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Abstract
Wasting of connective tissues including skin, bone, and cartilage have been closely associated with elevated matrix
 .  .metalloproteinase MMP activity and depressed collagen content in the streptozotocin STZ -induced diabetic rat, while
tetracyclines have been reported to normalize total body weight, skin hydroxyproline and collagen content in this model, in
part through inhibition of MMPs. In the present study, we report the effect of CMT-1, a chemically modified tetracycline
that lacks antimicrobial properties but retains divalent cation binding and MMP inhibitory activity, on diabetic skin collagen
 .synthesis and steady-state levels of procollagen a1 I mRNA. Male, 4-month old Sprague–Dawley rats received a single
injection of 75 mgrkg STZ or citrate vehicle alone and diabetic status was confirmed by positive glucosuria. Some diabetic
animals received 10 mgrday of CMT-1 by oral gavage and, 28 days after STZ treatment, body weight, blood glucose
values and the in vivo rates of skin collagen production were measured using the pool-expansion technique. Steady-state
 . 32levels of procollagen a1 I mRNA were analyzed 21 days after STZ treatment by hybridization of total RNA with a P
 .labelled cDNA to rat type I procollagen a1 I mRNA in a dot-blot assay. STZ treatment was found to significantly depress
body weight, skin collagen hydroxyproline content, the in vivo rate of collagen production, and hybridizable levels of type I
 .procollagen a1 I mRNA. CMT-1 administered daily to STZ-treated rats inhibited the diabetic depression of these
parameters but had little or no effect on non-diabetic controls or on STZ-induced hyperglycemia. Thus, in addition to the
inhibition of MMP mediated extracellular collagen degradation, these results suggest CMT-1 also acts to inhibit diabetic
connective tissue breakdown in STZ-induced diabetes by increasing both steady-state levels of type I procollagen mRNA
 .and collagen synthesis through mechanism s that are independent of the antibacterial properties of tetracyclines. q 1998
Elsevier Science B.V.
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1. Introduction
Wasting of connective tissues has historically been
a prominent feature of uncontrolled insulin-dependent
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 .diabetes mellitus. In the streptozotocin STZ -induced
diabetic rat, atrophy of connective tissues including
w x w xskin 1,2 , bone and cartilage 3,4 have been closely
associated with depressed collagen content. Since the
total tissue collagen mass is the result of both rates of
formation and degradation, depressed connective tis-
sue collagen content associated with STZ-induced
diabetes may result from increased collagen degrada-
tion andror depressed levels of total collagen synthe-
sis. Indeed, increased skin collagenase activity and
excessive skin collagen degradation have been re-
w xported in the STZ-induced diabetic rat 2,5 and
increased collagen degradation has been proposed as
a possible mechanism for depressed accumulation of
newly synthesized collagen observed in this model
w x6 . However, direct depression of collagen synthesis
in the STZ-induced diabetic rat has also been re-
ported for several connective tissues including skin
w x w x w x7 , gingiva 8 and bone 9,10 . These results suggest
that depressed collagen content observed in the STZ-
induced diabetic rat may be the result of multiple
factors active at several regulatory points.
Tetracyclines have been reported to inhibit exces-
sive connective tissue degradation in several patho-
logic processes including STZ-induced diabetes
w x6,11–13 . Tetracyclines are known to be potent in-
hibitors of extracellular matrix metalloproteinases
 .MMPs , including the three collagenases MMP-1,
MMP-8 and MMP-13, and two gelatinases MMP-2
w xand MMP-9 14,15 , and are thought to act, in part,
through the chelation of divalent cations required as
w xMMP cofactors 16,17 . It is therefore possible that
tetracyclines may increase total collagen production
in the STZ-induced diabetic rat through the inhibition
w xof extracellular MMPs 11 and intracellular proteoly-
w xsis 18 . In support of this hypothesis, doxycycline,
minocycline, and 4-dedimethylaminotetracycline, a
chemically modified tetracycline lacking antimicro-
bial properties but retaining divalent cation binding,
have all been reported to inhibit intracellular myo-
w xblast proteolysis in vitro 18 , perhaps through inhibi-
tion of Ca2q and Zn2q dependent proteinases
 . w xmyosinase 19 . This effect of tetracycline may have
relevance to diabetes-induced wasting in muscle tis-
sue as well.
However, several studies have also reported direct
anabolic effects on collagen synthesis by tetra-
cyclines in the STZ-induced diabetic rat. Tetracycline
treatment of diabetic rats resulted in increased total
w xbody weight and skin collagen mass 11,12 , incorpo-
w3 xration of H proline into periodontal ligament fibrob-
w xlasts 20 , total skin RNA content, and the in vivo
w xrate of collagen production 12 . Taken together,
these results suggest that tetracyclines act at several
sites to inhibit the loss of collagen in various tissues
during poorly controlledruncontrolled diabetes,
specifically through inhibition of collagen degrada-
tion and stimulation of collagen synthesis.
The present study was designed to further charac-
terize the anabolic effect of tetracyclines on skin
collagen synthesis in the STZ-induced diabetic rat.
We first addressed whether the prevention of the loss
of skin collagen in the STZ-induced diabetic rat was
due to the antibiotic or divalent ion chelation prop-
erty of tetracyclines by administration of a tetra-
cycline derivative lacking antimicrobial activity but
retaining divalent cation binding. Then, through anal-
ysis of in vivo rates of skin collagen production and
steady-state levels of type I procollagen mRNA, we
have begun to define the site in the biosynthetic
pathway at which tetracyclines may act to inhibit
STZ-induced depression of skin collagen synthesis.
Our results suggest that tetracyclines inhibit the
STZ-induced diabetic depression of skin collagen
synthesis, in part, through a non-antimicrobial mech-
anism, at a pre-translational site by enhancing
steady-state levels of type I procollagen mRNA.
2. Materials and methods
2.1. In ˝i˝o protocol
Four month old male Sprague–Dawley rats
Charles River Breeding Laboratories, Cambridge
.MA received, on day 0, an intravenous injection via
the tail vein of streptozotocin 2-deoxymethyl ni-
trosourea glucopyranose, STZ, Sigma, St. Louis, MO,
.75 mgrkg body weight dissolved in isotonic saline
 .  .and 0.1 M citrate buffer pH 4.5 diabetic group or
isotonic saline and 0.1 M citrate buffer alone control
.group . Diabetic status was verified using a test tape
 .for urine glucose Eli Lilly . Some STZ treated ani-
mals, beginning on day 0, also received 10 mgrday
 .for measurement of collagen protein synthesis or 5
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mgrday for measurement of steady state levels of
.type I procollagen mRNA of a chemically-modified
 .tetracycline 4-dedimethylamino tetracycline, CMT-1
 .in an aqueous 2% wrv carboxymethyl cellulose
suspension delivered by oral intubation diabeticq
.CMT group . CMT-1 was synthesized according to
w x w xMcCormick et al. 21 and Boothe et al. 22 and is a
tetracycline derivative lacking antimicrobial activity
but retaining its cation binding site at carbon-11 and
carbon-12 and associated MMP inhibitory activity
w x11,17 . Animals were maintained for 28 days and
given Purina Laboratory Rat Chow Ralston Purina,
.St. Louis, MO and water ad libitum.
2.2. Measurement of collagen protein synthesis
w xThe pool expansion approach 8 was used to
determine the effect of STZ induced diabetes and
CMT treatment on total skin collagen production.
Two in vivo labeling protocols were followed using
w3 xdifferent concentrations of H proline. Twenty-eight
days after STZ treatment, some animals received
w 3 xintraperitoneal injections of 2 mCi of 2,3 H proline
 .New England Nuclear, Cambridge, MA in 2.0 ml of
isotonic saline containing 800 mg L-proline and were
sacrificed 0.5 h later to measure intracellular procol-
lagen pools. Some animals received intraperitoneal
w 3 x injections of 1 mCi of 2,3 H proline New England
.Nuclear, Cambridge, MA in 2.0 ml of isotonic saline
containing 800 mg L-proline and were sacrificed 2 h
later to determine the effect on total collagen produc-
tion including the recently secreted extracellular frac-
tion. At completion of either labeling period, blood
was collected by intra-cardiac puncture after halothane
anesthesia induction. Serum glucose was determined
using a glucose oxidase assay kit Sigma, St. Louis,
.MO . Skin from the entire torso was removed as
w xpreviously described 23 and weighed.
Skin hydroxyproline an amino acid marker of
.collagen and proline content were determined by
 .extracting 1.5 g wet weight of minced, defatted skin
 .in 10% trichloroacetic acid TCA to yield TCA
soluble and insoluble fractions. The TCA soluble
fraction was lyophilized, dissolved in 2 ml of 1 M
ammonium acetate and the proline content deter-
mined by the tandem column procedure as previously
w xreported 24 . The TCA insoluble fraction was hydro-
w3 xlyzed in 6 M HCl at 1058C and the released H pro-
w3 xline and H hydroxyproline isolated using the tan-
dem column procedure. The prolyl-tRNA pool was
isolated and measured essentially as described by
w x  .Schneir et al. 12 . In brief, 6.0 g wet weight of
tissue was homogenized in 30 ml of cacodylic buffer
50 mM cacodylic acid, 1% sodium dodecyl sulfate,
. pH 6.0 using a polytron Brinkman Instruments,
.Luzern, Switzerland . The homogenate was extracted
 .in one volume phenolrcacodylic buffer 88:12, vrv ,
the aqueous fraction recovered, and nucleic acids
precipitated at y208C overnight by the addition of
2.5 volumes of 95% ethanol and collected by cen-
 .trifugation 10 000=g for 15 min at 48C . The pellet
was resuspended in 0.5 M ammonium hydroxide,
incubated at 378C for 1 h and ethanol precipitated as
described before. The pellet was lyophilized, dis-
solved in 2 ml of 1 M ammonium acetate and
processed for the isolation of proline as described
above. Skin collagen mass, relative collagen produc-
tion, fractional rate of collagen production and abso-
lute rate of collagen production were calculated from
w xthe above data as described by Schneir et al. 12 .
2.3. Measurement of steady state le˝els of type I
procollagen mRNA
Total RNA was isolated using a modification of
w xthe method of Chomczynski and Sacchi 25 . All
reagents were molecular biology grade and the usual
precautions against RNAse were followed including
the treatment of all solutions with 0.1% diethylpyro-
carbonate overnight followed by autoclaving. Phenol
was obtained from Boehringer Mannheim Indianapo-
.lis, IN while all other regents unless specified were
 .obtained from Fisher Scientific Piscataway, NJ .
Immediately after sacrifice, the rat skin was
weighed, minced and immersed in liquid nitrogen.
Five grams of frozen tissue was added to 12.5 ml
denaturing solution 4 M guanidinium isothiocynate,
25 mM sodium citrate, 0.5% sarcosyl, 100 mM 2-
.mercaptoethanol, pH 7.0 and homogenized using a
polytron in a sterile 50 ml capped centrifuge tube.
Added in succession to the homogenate were 2.5 ml
 .of 2 M sodium acetate pH 4.5 , 12.5 ml water-
saturated phenol and 2.5 ml of chloroformrisoamyl
 .alcohol 24:1, vrv . The suspension was mixed thor-
oughly for 10 s, placed on ice for 15 min and cleared
by centrifugation at 10 000=g for 20 min at 48C.
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The aqueous phase was recovered and transferred to
a baked 30 ml Corex centrifuge tube, 1 volume of
isopropanol added, and RNA precipitated at y208C
overnight. The precipitate was collected by centrifu-
gation at 10 000=g for 20 min at 48C. The pellet
was redissolved in 5.0 ml of denaturing solution and
allowed to precipitate with 1 volume isopropanol at
y208C for 3 h. The precipitate was collected by
centrifugation at 10 000=g for 20 min at 48C, the
pellet washed once with cold 80% ethanol, and
lyophilized. The pellet was dissolved in minimal
double distilled sterile H O and total RNA quanti-2
tated by optical absorbance at 260.
A series of 1:2 dilutions starting from an initial 10
mg of total RNA was prepared and dotted onto a
nylon membrane Zeta Probe, BioRad Laboratories,
.Hercules, CA immobilized in a vacuum manifold
 .Schleicher and Schuell, Keane, NH . The dot blot
was baked under vacuum at 808C for 1 h. The blot
was prehybridized 6 h at 508C in 12 ml of hybridiza-
tion solution 50% deionized formamide, 4= SSPE
600 mM sodium chloride, 40 mM sodium phos-
phate, 4 mM ethylenediamine tetraacetic acid
 . .  .EDTA , pH 7.4 , 1.0% sodium dodecylsulfate SDS ,
0.5% Blotto 10% Carnation non-fat dry milk in
.0.025% sodium azide , 0.5 mgrml sheared, dena-
.tured salmon sperm DNA with constant shaking in a
Dubnoff water bath in a customized polyethylene
bag.
The blot was hybridized 12 h at 508C in 12 ml of
hybridization solution containing a 32P labelled cDNA
 .to the 3 prime triple helical domain of rat pro a1 I
w xcollagen mRNA 26 . The insert was digested from
the plasmid cloning vector by PST I, isolated on
0.8% agarose gels containing 0.5 mgrml ethidium
bromide, visualized by ultraviolet illumination, and
recovered by continued electrophoresis onto a What-
man 3MM paper backed by dialysis membrane. The
insert was eluted in extraction buffer 200 mM sodium
.chloride, 50 mM Tris–HCl, 1 mM EDTA , extracted
 .with chloroformrphenol 1:1 and ethanol precipi-
 .tated. The insert 10 ng was labeled to greater than
6.8=108 cpmrmg DNA by random priming with T7
 .polymerase PrimeIt, Stratagene, La Jolla, CA in the
w 32 xpresence of a- P deoxycytidine triphosphate
)3000 Cirmmol, Amersham, Arlington Heights,
. w xIL , as described by Feinberg and Vogelstein 27 .
The labelled cDNA was denatured at 958C for 5 min
prior to addition to the hybridization bag. After hy-
bridization, the blot was washed once in 2= SSPE,
once in 2= SSPE in 0.1% SDS, and twice in 1=
SSPE in 0.1% SDS. All washes were conducted at
room temperature for 10 min with constant shaking.
The hybridized blot was exposed to preflashed X
 .OMAT AR film Kodak, Rochester, NY with en-
hancing screens at y808C overnight.
The resulting autoradiograph was quantitated using
an LKB Ultrascan laser densitometer and Pharmacia
Gel Scan XC software Pharmacia LKB Biotechnol-
.ogy, Piscataway, NJ . The relative level of hybridiz-
 .able pro a1 I collagen mRNA, reported as the
treatedrcontrol ratio for each group, was determined
by first plotting the optical density vs. the dilution for
each dot, then calculating the slope of the linear
portion of the resulting relationship and dividing the
slope by that generated by the control as previously
w xdescribed 28 . Data was analyzed for statistical sig-
nificance using a two tailed Student’s t-test.
3. Results
STZ treatment markedly depressed total body
weight and increased blood glucose levels, however,
the daily administration of CMT-1 was able to inhibit
the STZ-induced depression of body weight but not
blood glucose values. As noted in Table 1, the dia-
betic group was markedly hyperglycemic and failed
to gain, but on average lost, body weight 28 days
after STZ treatment when compared to the sham-
treated control group. The daily oral administration of
10 mgrday of CMT-1 to the STZ-treated group
 .diabeticqCMT-1 resulted in an increase in body
weight without any significant effect on blood glu-
cose levels when compared to the STZ treated di-
.abetic group. Therefore, CMT-1, administered daily
over the 28-day time period of the study, partially
inhibited the loss in body weight associated with
STZ-induced diabetes without any significant effect
on STZ-induced hyperglycemia.
The failure to increase body weight observed 28
days following STZ treatment was associated with
 .decreased skin collagen content Table 2 . Total skin
collagen was estimated by measuring the hydroxy-
proline content in skin of 28-day control, diabetic,
and diabeticqCMT-1 treatment groups. As reported
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Table 1
Body weight and blood glucose levels of CMT-1 treated diabetic rats
 .  .  .Treatment group Treatment day n Body weight g Blood glucose mgrdl
 .Control 0 5 378"11 98"5
 .Control 28 10 474"24 108"3
a a .Diabetic 28 10 322"26 662"9
b a .DiabeticqCMT-1 28 10 391"13 638"9
Male, 4-month-old Sprague–Dawley rats received a single injection of 75 mgrkg STZ or citrate vehicle alone and diabetic status
confirmed by positive glucosuria. Some diabetic animals received 10 mgrday of CMT-1 and 28 days after STZ treatment body weight
 .and blood glucose were determined. Values are the mean"S.D. for n animals.
ap-0.001 vs. 28 day control.
bp-0.001 vs. 28 day diabetic.
in Table 2, skin from the diabetic group contained
53% less hydroxyproline than the non-diabetic con-
trol animals on a per wet weight basis. However, skin
from diabetic rats given 10 mg CMT-1 daily, con-
tained 30% less hydroxyproline than 28-day controls
but 50% more hydroxyproline than the diabetic group.
Therefore, the daily administration of CMT-1 par-
tially inhibited the decrease in total skin collagen
content associated with STZ-induced diabetes and
was correlated with the effect of CMT-1 on total
STZ-induced diabetic body weight reported in Table
1.
Tetracyclines are known inhibitors of metallopro-
w xteinases 16 and excessive skin collagenase activity
has been reported in the STZ-induced diabetic rat
w xmodel 2,5 . However, to address whether CMT-1
also has direct, anabolic effects on diabetic collagen
synthesis, as earlier studies using tetracyclines with
w xantibiotic properties have suggested 12,20 , levels of
collagen protein synthesis were measured in vivo
w3 xusing H proline labeling and the pool expansion
w xtechnique 8 . Twenty-eight days after STZ adminis-
tration, animals received a single, intraperitoneal in-
w3 xjection containing 2 mCi of H proline and 800 mg
unlabeled proline. Two separate in vivo labeling in-
tervals of 0.5 and 2 h were followed. The 0.5-h in
vivo labeling period estimated intracellular collagen
production, since collagen synthesized during this
time interval has been reported to be primarily intra-
cellular and thus protected from the action of extra-
w xcellular proteases 29 . The 2-h in vivo labeling pe-
riod was used to estimate the overall rate of newly
synthesized skin collagen accumulation, both intra-
cellular procollagen and recently secreted collagen.
Since insulin has well documented effects on con-
w xnective tissue amino acid and hexose transport 30 ,
we first measured the specific radioactivity of prolyl
tRNA pools after STZ, or STZqCMT-1 treatment.
Total RNA was isolated from 6.0 g of frozen tissue
and hydrolyzed by treatment with sodium hydroxide.
The proline content of the hydrolysate was isolated
by tandem column chromatography and quantitated
Table 2
Skin collagen mass of CMT-1 treated diabetic rats
 .  .Treatment group n Skin collagen mg hydroxyproline % difference
vs. C vs. D
 .Control 8 1044"91
a .Diabetic 8 491"67 y53
a a .DiabeticqCMTy1 9 736"103 y30 q50
 .Values are the mean"S.D. skin hydroxyproline content of 1.5 g of minced defatted skin of n animals 28 days after receiving 75
 .  .  .mgrkg of STZ, diabetic , STZq10 mgrday CMT-1 diabeticqCMT-1 or citrate vehicle alone control as described in Section 2.
ap-0.001.
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Table 3
w3 xSpecific radioactivity of skin H prolyl tRNA pools
 .  .Treatment group n 0.5 h label n 2 h label
 .  .Control 3 3902"392 4 1313"210
 .  .Diabetic 5 4200"462 5 1508"179
 .  .DiabeticqCMT-1 5 2688"2440 5 1197"218
w3 xValues are the mean"S.D. dpm H prolinermg proline for 6.0
 .g of skin from n animals 28 days after receiving 75 mgrkg of
 .  .STZ, diabetic , STZq10 mgrday CMT-1 diabeticqCMT-1 or
 .citrate vehicle alone control . To determine the effect of diabetes
and diabetesqCMT-1 treatment on skin collagen production,
w3 xanimals received 2 mCi of H proline 0.5 h or 1 mCi of
w3 xH proline 2 h prior to sacrifice. The prolyl tRNA pool specific
radioactivity was determined as described in Section 2.
by comparison of chromatographic peak heights with
known standards. The radioactivity associated with
the proline peak was then measured by liquid scintil-
lation spectroscopy. As shown in Table 3, little dif-
ference was detected in the specific radioactivity of
tissue prolyl tRNA pools in the 28-day control, dia-
betic, or diabeticqCMT-1 groups after either the 0.5
or 2-h in vivo labeling intervals. Therefore, any
w3 xchange in H proline incorporation into newly syn-
thesized protein observed among the treatment groups
of this study was not due to changes in the specific
activity of the prolyl tRNA pools.
The in vivo rate of collagen production was mea-
sured using 1.5 g of minced skin extracted in 10%
TCA, to remove unincorporated isotope, followed by
acid hydrolysis. The liberated hydroxyproline and
proline was isolated by tandem column chromatogra-
phy, quantitated by comparison of peak heights with
known standards, and the associated radioactivity
measured by liquid scintillation spectroscopy. The
values obtained were combined with the specific
radioactivity of the prolyl tRNA pool and the abso-
lute rate of skin collagen production calculated. The
results are reported in Table 4. The levels of skin
collagen synthesis in the diabetic group were approx-
imately 10% of control values after both 0.5 and 2-h
labeling intervals. However, skin collagen synthesis
in diabetic rats treated with CMT-1 was not signifi-
cantly different from that of the non-diabetic group.
Therefore, these results suggest CMT-1 had direct
anabolic effects on diabetic skin collagen synthesis in
this model. Furthermore, CMT-1 appeared to act
through a mechanism separate from the inhibition of
extracellular metalloproteinases previously reported
w xfor tetracyclines 12,17 , since the rate of skin colla-
gen production in diabetic rats treated daily with
CMT-1 was elevated to a similar level after both the
0.5 and 2-h labeling intervals.
In several systems, collagen production can be
regulated, at least in part, through intracellular degra-
w xdation of newly synthesized collagen protein 31 and
in fact, intracellular procollagen degradation is en-
w xhanced during experimental diabetes 24 . However,
Table 4
Absolute rate of rat skin collagen production
3 3 3 . w x w x w xTreatment group n H HYPq H PRO H prolyl tRNA Absolute rate
y3 y3 .  .  .dpmrskin =10 dpmrmmol =10 mmolrh
Control
 .0.5 h 3 2394"526 449"45 21.2"3.2
 .2 h 4 3310"1195 151"24 22.9"10.9
Diabetic
a .0.5 h 3 222"65 474"67 1.9"0.8
a .2 h 5 619"151 173"21 3.6"1.1
DqCMT-1
 .0.5 h 3 1185"750 368"286 18.2"13.5
 .2 h 5 2172"555 137"25 15.9"3.3
Values are the mean"S.D. for the radioactivity of the hydroxyproline plus proline pools, specific activity of the prolyl tRNA pool, and
 .  .rate of collagen production for skin samples from n animals 28 days after receiving 75 mgrkg of STZ, diabetic , STZq10 mgrday
 .  .CMT-1 diabeticqCMT-1 or citrate vehicle alone control as described in Section 2. Results after both 0.5 and 2-h in vivo labeling
periods are presented.
ap-0.01.
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in most tissues, collagen synthesis is regulated proxi-
mally, at the level of transcription or translation
w x28,29 . To address the possibility that CMT-1 may
stimulate collagen synthesis at a pretranslational site
in the STZ-induced diabetic rat, we asked whether
steady-state levels of type I procollagen mRNA were
altered in the diabetic or diabeticqCMT-1 groups.
Total skin RNA was isolated from diabetic, non-di-
abetic, diabeticqCMT-1, and non-diabeticqCMT-1
groups and quantitated by optical absorbance at 260
nm. A series of dilutions was prepared for each
sample, starting from an initial 10 mg of total RNA,
and dotted onto nylon membranes. The blot was
hybridized with a 32P-labelled cDNA to the 3 prime
 .triple helical domain of rat pro a1 I mRNA as
described in Section 2, and the resulting autoradio-
graph of the hybridized RNA dot blot shown in Fig.
1.
The RNA dot blot was quantitated by optically
scanning the dilution series for each sample. The
optical density vs. the RNA dilution for each dot was
plotted and the slope of the linear portion of the
resulting relationship was compared to that of con-
 .trol. The relative levels of pro a1 I mRNA, ex-
pressed as a percent of control levels, is presented for
each of the four treatment groups in Fig. 2. Although
variation in the mean level of hybridization was
noted within each group, the diabetic group had
approximately 30% of the level of hybridizable pro
 .a1 I mRNA seen in the non-diabetic groups. Treat-
ment of diabetic animals with CMT-1 significantly
 .increased hybridizable pro a1 I mRNA to a level
similar to that of non-diabetic controls, while in
non-diabetic animals, daily CMT-1 treatment had
 .little effect on hybridizable levels of pro a1 I
mRNA. Therefore, the stimulation in the rate of
collagen protein synthesis observed in diabetic ani-
 .mals treated daily with CMT-1 Table 4 correlated
 .with increased steady-state levels of pro a1 I mRNA
 .Fig. 2 . These results imply that CMT-1 has direct
Fig. 1. Dot Blot of CMT-1 treated diabetic rat RNA hybridized with pa1R1. A series of four 1:2 dilutions starting with an initial 10 mg
 .  .  .of total RNA from n animals 21 days after receiving 75 mgrkg of STZ, Diabetic , STZq5 mgrday CMT-1 DiabeticqCMT-1 or
citrate vehicle or control alone was blotted onto a nylon membrane. The blot was hybridized with a 32P-labelled cDNA to the 3X triple
 . w xhelical domain of rat pro a1 I mRNA 23 , and subsequently exposed to X OMAT AR film with enhancing screens at y808C overnight
as described in Section 2.
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 .Fig. 2. Relative levels of proa1 I mRNA. The series of dilutions
for each sample in Fig. 1 was optically scanned, the optical
density vs. the dilution was plotted for each dot, the slope of the
linear portion of the resulting relationship for each sample calcu-
lated and averaged within each group and compared to control.
 .  .The mean"S.D. for control N , controlqCMT-1 NqCMT-1 ,
 .  .diabetic D , and diabeticqCMT-1 DqCMT-1 is given as a
 .percent of control 100% . ) p-0.05.
anabolic effects on diabetic skin collagen synthesis in
the STZ-induced diabetic rat including the stimula-
 .tion of steady-state levels of pro a1 I mRNA.
4. Discussion
Treatment of 4-month old Sprague–Dawley rats
with a single dose of STZ after 28 days resulted in
the expected diabetic manifestations including total
body weight loss, decreased skin collagen content
and marked hyperglycemia; effects of STZ well doc-
w xumented in previous reports 1–3,9,11,12,23,24 . The
oral administration of 10 mgrday CMT-1 inhibited
the STZ-diabetes induced loss in body weight and
decreased skin collagen content without significant
inhibition of STZ-induced hyperglycemia. Thus,
CMT-1, a tetracycline derivative without antibiotic
w xproperties but retaining divalent cation binding 11 ,
was able to replicate results of earlier studies which
reported inhibition of connective tissue wasting in
STZ-induced diabetic adult rats by tetracyclines with
w xantibiotic properties 11,12,20 . The results of the
present study, together with those using germ-free
w xanimals 6 , suggest that inhibition of STZ-induced
diabetic connective tissue wasting by tetracyclines is
not mediated by antibiotic but rather other properties
of tetracyclines, possibly involving the chelation of
divalent cations.
While the inhibitory effects of tetracyclines on
excessive collagen degradation associated with STZ-
w xinduced diabetes have been well documented 6,11,17
and act presumably through divalent cation chelation
w x11 and inhibition of host-derived matrix metallopro-
w xteinases 17 , the present study was specifically de-
signed to address the anabolic effects of tetracyclines
on diabetic skin collagen metabolism. It is of interest
to note that, in the present study, CMT-1 was unable
to completely reverse the STZ-induced loss of body
weight and skin collagen mass. These results are in
agreement with other studies of tetracyclines in STZ-
w xinduced diabetes 11,12 . Although it is possible that
incomplete reversal of STZ-induced weight loss and
associated skin collagen content could have resulted
due to the lack of pair feeding or the use of sham
intubation controls for daily CMT-1 oral administra-
tion, it is more likely that tetracyclines are not direct
antagonists of the diabetogenic effects of STZ but
rather exert their anabolic effects on skin collagen
synthesis through mechanisms distinct from inhibi-
tion of STZ-induced hyperglycemia and hypoinsu-
linemia.
Along these lines, a primary finding of the present
study was that the reduction of total skin collagen
content and suppression of skin collagen synthesis in
the diabetic rat were both inhibited by the daily oral
administration of CMT-1. These results agree with
prior studies using tetracyclines with antibiotic prop-
w xerties 11,12,20 . The increased levels of skin colla-
gen synthesis observed in the diabeticqCMT-1
group, when compared to the diabetic group alone,
was apparently not due to changes in the specific
activity of the prolyl tRNA pool. Rather, in skin from
STZ-induced diabetic rats, CMT-1 appeared to act
pretranslationally in the collagen biosynthetic path-
 .way, since steady state levels of pro a1 I collagen
mRNA from the diabeticqCMT-1 group were not
significantly different from those of non-diabetic or
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non-diabeticqCMT-1 groups. Furthermore, the ef-
 .fect of CMT-1 on steady state levels of pro a1 I
collagen mRNA correlated with levels of collagen
protein synthesis.
 .Insulin is known to stimulate levels of pro a1 I
collagen mRNA and protein synthesis, and insulin
 .removal rapidly returns pro a1 I collagen mRNA
and protein synthesis to basal levels, presumably
through decreased collagen gene transcription and
w xmRNA half life 28 . In the present study, levels of
 .pro a1 I collagen mRNA from skin of diabetic rats
was 30% of that of non-diabetic controls. However,
the administration of CMT-1 to non-diabetic rats did
 .not increase steady state levels of pro a1 I collagen
mRNA while, in a separate in vitro study, the addi-
tion of CMT-1 did not result in increased myoblast
w xprotein synthesis 18 . The daily administration of
CMT-1 did prevent the decrease in steady state levels
 .of pro a1 I collagen mRNA associated with STZ-
induced diabetes over the 28-day study period and is
in agreement with prior reports of minocycline nor-
malization of skin collagen synthesis and ribosomal
w xmass in STZ-induced diabetic rats 12 . Therefore,
the anabolic effect of CMT-1 on skin collagen syn-
thesis in the STZ-induced diabetic rat appeared medi-
ated through the inhibition of depressed steady state
 .levels of pro a1 I collagen mRNA, effected per-
 .haps, in part, through prolonged pro a1 I collagen
mRNA half life.
Two other studies have reported tetracycline-
induced changes in steady state message levels. The
addition of doxycycline or CMT-1 to keratinocyte
cultures after 24 h decreased protein levels of gelati-
nases MMP-2 and MMP-9. The decreased expression
of MMP-2 was associated with decreased hybridiz-
able levels of MMP-2 mRNA by Northern blot analy-
sis and an alteration in cell shape from flattened to
spherical, suggesting a loss of cell–cell or cell-matrix
contacts with tetracycline addition. It was proposed
that doxycycline and CMT-1 may directly decrease
MMP-2 mRNA at a proximal site through alteration
in rates of MMP-2 transcription or MMP-2 mRNA
degradation. It was also proposed that doxycycline
and CMT-1 may act indirectly at the cell membrane
by decreasing MMP-2 mRNA, through chelation of
divalent cations required for cell adhesion molecules,
with subsequent changes in gene expression mediated
w xthrough signal transduction pathways 32 .
Evidence for the former, direct role of tetra-
cyclines in the regulation of gene expression has
come from a report of depressed steady state
 .stromelysin MMP-3 mRNA message levels by
tetracycline in cultured keratinocytes after MMP-3
 . w xinduction by interleukin-1 Il-1 33 . Decreased
steady state levels of MMP-3 mRNA were correlated
with decreased rates of MMP-3 transcription, since a
plasmid construct consisting of the MMP-3 promoter
ligated to the bacterial chloramphenicol acetyl trans-
 .ferase CAT coding sequence, when transfected into
human skin fibroblasts, resulted in a dose-dependent
decrease by tetracycline in MMP-3 transcription after
induction of MMP-3 expression by Il-1. Inhibition of
MMP-3 expression by tetracycline was found to be
independent of the AP-1 domain, however, it was
noted that tetracycline alone was not able to depress
w xMMP-3 expression below constitutive levels 33 .
Support for an indirect, signal transduction-media-
ted effect of tetracyclines on steady-state message
levels has come from reports that protein kinase C
mediated phosphorylation is inhibited in a dose-de-
w xpendent fashion by tetracyclines 34 and that protein
kinase C constitutes a major signal transduction path-
w xway in skin keratinocytes 35 . Furthermore, protein
kinase C phosphorylation has been implicated in
 .poly A tail removal and subsequent mRNA decay
w xfor TNF-a mRNA 36 . Protein kinase C has been
demonstrated to both shorten or prolong message half
 w x.lives for other mRNA as well reviewed in Ref. 37 .
These reports suggest that many of the pleiotropic
effects tetracyclines exert, such as alteration in steady
state mRNA levels, may act through divalent cation
dependent processes including calcium-calmodulin
w xdependent signal transduction pathways 38 .
It is also possible that tetracyclines may exert
some of their anabolic effects on skin collagen syn-
thesis through a systemic factor. Since a close corre-
lation between body weight and skin collagen synthe-
w xsis was found in this and in earlier studies 11,12 ,
tetracyclines have been proposed to stimulate the
synthesis or release of a general systemic anabolic
 .factor, such as insulin like growth factor 1 IGF-1
w x12 . The present study did not monitor serum levels
of IGF-1, however, recent studies have shown that
tetracyclines may effect metabolic processes impor-
tant to diabetic complications. In this regard, excess
production of cytokines and prostaglandin E , upreg-2
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ulation of inducible nitric oxide synthase and non-en-
zymatic glycosylation of collagen and other long-lived
proteins may all contribute to collagen loss through
decreased collagen synthesis andror increased colla-
gen degradation during diabetes. In addition, these
metabolic processes have all been found to be ef-
w xfected by tetracyclines and CMTs 4,39,40 .
However, it is clear from the results of the present
w xand related studies 6,11–13,18,20 that tetracyclines
function at several sites in the collagen biosynthetic
pathway to inhibit connective tissue wasting associ-
ated with STZ-induced diabetes. These include the
inhibition of extracellular matrix metalloproteinases
and the stimulation of skin collagen synthesis through
mechanisms independent of the antimicrobial proper-
ties of tetracyclines. To effect such disparate cellular
functions, it would appear probable that a common
biochemical mechanism, such as calcium depen-
dence, could be a common factor. If this hypothesis
is correct, the opportunity arises to design future
tetracycline derivatives that can inhibit specific diva-
lent cation dependent pathologic processes without
the concomitant selection of antibiotic resistant mi-
crobial species.
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